CFGS
PLRX icon

Concourse Financial Group Securities’s Pliant Therapeutics PLRX Stock Holding History

Concourse Financial Group Securities’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7
Closed -$166 – 2427
2023
Q1 		$186 Buy
+7
New +$199 ﹤0.01% 2314

Other funds holding PLRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Concourse Financial Group Securities's PLRX Position: Q2 2023 in Review

Concourse Financial Group Securities sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 7 shares — an estimated $166 sold.

Concourse Financial Group Securities first reported a position in PLRX in Q1 2023 and held it in 1 quarter. The position peaked at $186 in Q1 2023. 143 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

  • Concourse Financial Group Securities reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Concourse Financial Group Securities sold 7 Pliant Therapeutics shares in Q2 2023, an estimated $166.
  • Concourse Financial Group Securities first reported a position in Pliant Therapeutics in Q1 2023 and held it in 1 quarter.
  • Concourse Financial Group Securities's Pliant Therapeutics position peaked at $186 in Q1 2023.
  • 143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on Concourse Financial Group Securities's 13F filing for Q2 2023, filed 10 Aug 2023.